Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Imugene Limited

Capitalization 73.95M 52.81M 45.35M 40.99M 39.25M 71.69M 4.85B 483M 193M 2.33B 198M 194M 8.33B P/E ratio 2026 *
-1.28x
P/E ratio 2027 * -1.73x
Enterprise value 73.95M 52.81M 45.35M 40.99M 39.25M 71.69M 4.85B 483M 193M 2.33B 198M 194M 8.33B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87%
Yield 2026 *
-
Yield 2027 * -
1 day-17.39%
1 week-20.83%
Current month-20.83%
1 month-29.63%
3 months-38.71%
6 months-33.33%
Current year-47.95%
1 week 0.18
Extreme 0.18
0.25
1 month 0.18
Extreme 0.18
0.27
Current year 0.18
Extreme 0.18
0.41
1 year 0.18
Extreme 0.18
1.39
3 years 0.18
Extreme 0.18
5.1
5 years 0.18
Extreme 0.18
21.25
10 years 0.18
Extreme 0.18
21.25
Manager TitleAgeSince
Chief Executive Officer - 01/11/2016
Director of Finance/CFO - 04/03/2025
Chief Tech/Sci/R&D Officer - 01/09/2023
Director TitleAgeSince
Chairman 70 31/10/2012
Director/Board Member - 28/03/2018
Director/Board Member 66 23/04/2019
Change 5d. change 1-year change 3-years change Capi.($)
-17.39%-20.83%-83.56%-95.70% 52.81M
-1.10%-6.35%-7.83%-6.43% 44.92B
+1.03%+2.81%+25.85%+41.23% 33.88B
+0.98%-8.44%+16.94%+45.41% 30.76B
-4.27%-1.74%-9.46%-13.35% 28.69B
-0.93%-1.62%+168.50%+376.20% 19.59B
+0.25%+0.54%+74.06%+126.46% 14.76B
-2.46%+0.30%+38.35%+166.08% 13.25B
-1.01%-5.72%+24.94%-0.10% 13.06B
-5.37%+2.17%+22,573.45%+3,414.48% 12.12B
Average -3.03%+0.59%+2,282.12%+405.43% 21.11B
Weighted average by Cap. -1.11%-0.24%+1,324.48%+260.25%

Financials

2026 *2027 *
Net sales - -
Net income -52.7M -37.64M -32.32M -29.21M -27.97M -51.09M -3.46B -344M -138M -1.66B -141M -138M -5.93B -52.7M -37.64M -32.32M -29.21M -27.97M -51.09M -3.46B -344M -138M -1.66B -141M -138M -5.93B
Net Debt - -
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
15
Date Price Change Volume
11/03/26 0.1900 $ -17.39% 4,543,023
09/03/26 0.2300 $ -2.13% 468,174
06/03/26 0.2350 $ -4.08% 523,611
05/03/26 0.2450 $ +2.08% 859,897
04/03/26 0.2400 $ +17.07% 2,341,253
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2300AUD
Average target price
0.8200AUD
Spread / Average Target
+256.52%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW